JP2013533253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533253A5 JP2013533253A5 JP2013518241A JP2013518241A JP2013533253A5 JP 2013533253 A5 JP2013533253 A5 JP 2013533253A5 JP 2013518241 A JP2013518241 A JP 2013518241A JP 2013518241 A JP2013518241 A JP 2013518241A JP 2013533253 A5 JP2013533253 A5 JP 2013533253A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- enantiomer
- atoms
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/827,505 | 2010-06-30 | ||
| US12/827,505 US9610274B2 (en) | 2010-06-30 | 2010-06-30 | Methods for treating bipolar disorder |
| PCT/KR2011/004676 WO2012002687A2 (en) | 2010-06-30 | 2011-06-27 | Methods for treating bipolar disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533253A JP2013533253A (ja) | 2013-08-22 |
| JP2013533253A5 true JP2013533253A5 (enExample) | 2014-08-07 |
| JP5881692B2 JP5881692B2 (ja) | 2016-03-09 |
Family
ID=45400168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518241A Active JP5881692B2 (ja) | 2010-06-30 | 2011-06-27 | 双極性障害を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9610274B2 (enExample) |
| EP (1) | EP2590645B1 (enExample) |
| JP (1) | JP5881692B2 (enExample) |
| KR (1) | KR101828934B1 (enExample) |
| CN (1) | CN102985085B (enExample) |
| AU (1) | AU2011272156B2 (enExample) |
| BR (1) | BR112012033738A2 (enExample) |
| CA (1) | CA2801241C (enExample) |
| ES (1) | ES2654615T3 (enExample) |
| MX (2) | MX360030B (enExample) |
| PL (1) | PL2590645T3 (enExample) |
| RU (1) | RU2653408C2 (enExample) |
| WO (1) | WO2012002687A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1890684T3 (pl) | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| AU2010270971B2 (en) | 2009-06-22 | 2015-08-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| RU2019114940A (ru) | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
| DK3021838T3 (da) | 2013-07-18 | 2020-08-24 | Jazz Pharmaceuticals Ireland Ltd | Behandling af fedme |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| TWI655179B (zh) | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| CN121202730A (zh) | 2016-09-06 | 2025-12-26 | 爱尔兰贾兹制药有限公司 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| JP7074750B2 (ja) | 2016-10-06 | 2022-05-24 | ジャズ ファーマスティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール化合物およびその使用 |
| CN110290788A (zh) * | 2016-12-14 | 2019-09-27 | 爱思开生物制药株式会社 | 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 |
| KR20200016889A (ko) | 2017-06-02 | 2020-02-17 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 과다 졸림증을 치료하기 위한 방법 및 조성물 |
| SG11202000817SA (en) | 2017-07-31 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Carbamoyl phenylalaninol analogs and uses thereof |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| KR20240021189A (ko) * | 2021-06-11 | 2024-02-16 | 에스케이바이오팜 주식회사 | 자폐 스펙트럼 장애(asd)를 치료하는 방법 |
| CN121620365A (zh) | 2023-06-29 | 2026-03-06 | 艾克萨姆治疗股份有限公司 | 向哺乳期妇女施用索安非托的方法 |
| AU2025216819A1 (en) * | 2024-01-29 | 2026-07-09 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
| WO2026125068A1 (en) | 2024-12-10 | 2026-06-18 | Noucor Health, S.A. | Process to obtain solriamfetol hydrochloride |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ314570A (en) | 1993-06-10 | 2000-11-24 | Lilly Co Eli | Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2240060C (en) | 1996-10-10 | 2007-07-17 | Sk Corporation | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same |
| AU4674797A (en) | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| TW402591B (en) | 1997-07-11 | 2000-08-21 | Janssen Pharmaceutica Nv | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| KR20010043032A (ko) | 1998-04-28 | 2001-05-25 | 도모따께 다께시 | 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체 |
| US20010029262A1 (en) | 1998-06-29 | 2001-10-11 | Sethi Kapil Dev | Method of treatment or prophylaxis |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| US20010034320A1 (en) | 2000-01-18 | 2001-10-25 | Hans-Michael Brecht | NK1-receptor antagonists for treating restless legs syndrome |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| MXPA03007721A (es) | 2001-02-27 | 2004-11-12 | Johnson & Johnson | Compuesto de carbamato para su uso en el tratamiento del dolor. |
| RS50676B (sr) | 2001-02-27 | 2010-06-30 | Ortho-Mcneil Pharmaceutical Inc. | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja |
| EP1390034A4 (en) | 2001-04-03 | 2005-07-13 | Merck & Co Inc | N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS |
| CA2449249A1 (en) | 2001-06-12 | 2002-12-19 | Merck & Co., Inc. | Nr2b receptor antagonists for the treatment or prevention of migraines |
| US20040115263A1 (en) | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
| WO2004026868A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Japan Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| PL1664036T3 (pl) | 2003-09-03 | 2012-04-30 | Pfizer | Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| RU2007119648A (ru) * | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| MX2007012463A (es) | 2005-04-08 | 2007-11-07 | Pfizer Prod Inc | Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i. |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| PL1890684T3 (pl) | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| US8552060B2 (en) | 2005-06-22 | 2013-10-08 | Sk Biopharmaceuticals Co., Ltd. | Methods for treatment of sexual dysfunction |
| EP1928451B1 (en) | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
| EP1754476A1 (en) | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| AU2007313017A1 (en) | 2006-10-13 | 2008-04-24 | Janssen Pharmaceutica, N.V. | Phenylalkylamino carbamate compositions |
| HUP0700370A2 (en) * | 2007-05-24 | 2009-04-28 | Richter Gedeon Nyrt | Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| AU2010270971B2 (en) | 2009-06-22 | 2015-08-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| KR101097605B1 (ko) | 2009-11-04 | 2011-12-22 | 알.에프 에이치아이씨 주식회사 | 도허티 증폭기 |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
-
2010
- 2010-06-30 US US12/827,505 patent/US9610274B2/en active Active
-
2011
- 2011-06-27 RU RU2012155118A patent/RU2653408C2/ru active
- 2011-06-27 ES ES11801093.3T patent/ES2654615T3/es active Active
- 2011-06-27 MX MX2016002438A patent/MX360030B/es unknown
- 2011-06-27 CN CN201180032698.XA patent/CN102985085B/zh active Active
- 2011-06-27 JP JP2013518241A patent/JP5881692B2/ja active Active
- 2011-06-27 AU AU2011272156A patent/AU2011272156B2/en active Active
- 2011-06-27 KR KR1020127032128A patent/KR101828934B1/ko active Active
- 2011-06-27 CA CA2801241A patent/CA2801241C/en not_active Expired - Fee Related
- 2011-06-27 EP EP11801093.3A patent/EP2590645B1/en active Active
- 2011-06-27 PL PL11801093T patent/PL2590645T3/pl unknown
- 2011-06-27 WO PCT/KR2011/004676 patent/WO2012002687A2/en not_active Ceased
- 2011-06-27 BR BR112012033738A patent/BR112012033738A2/pt not_active Application Discontinuation
- 2011-06-27 MX MX2012014686A patent/MX2012014686A/es not_active Application Discontinuation
-
2017
- 2017-02-14 US US15/432,479 patent/US9907777B2/en active Active